BACKGROUND: Metformin, an insulin-sensitizing agent, has been used successfully as the first-line drug to induce ovulation in women with polycystic ovary syndrome. There are, however, very few studies evaluating metformin treatment in women with clomiphene citrate (CC)-resistant polycystic ovaries (PCO). METHODS: Twenty infertile Chinese women aged <40 years, who had ultrasound features of PCO and remained anovulatory on CC, were randomized by computer using the sealed envelope method to receive placebo or metformin 500 mg three times a day for 3 months. Hormonal and metabolic profiles were determined before the therapy and were repeated after 3 months for women who failed to become pregnant within this period. Clomiphene was then added for one cycle to those women who did not ovulate after taking placebo or metformin alone. RESULTS: The median ovulation rate in the placebo group was 0% (range: 0-50%) after placebo only and 6.9% (range: 0-50%) after placebo and CC, whereas the corresponding rates in the metformin group were 0% (range: 0-22%) and 0% (range: 0-22%) respectively. There was no improvement in the ovulation rate despite a significant reduction of body mass index, serum testosterone and fasting leptin concentrations in the metformin group. CONCLUSIONS: Metformin treatment may result in successful ovulation only in certain subgroups of these women.
Introduction
Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age, affecting 5-10% of premenopausal women (Franks, 1995) . Women with this syndrome may present with menstrual irregularities, chronic anovulation, infertility, obesity and hyperandrogenism. Insulin resistance and compensatory hyperinsulinaemia are prominent features of PCOS (Dunaif, 1995) and occur when there is oligoor amenorrhea (Robinson et al., 1993) . Insulin concentrations are proported to hyperandrogenism because of increased production of ovarian androgen and decreased synthesis of sex hormone-binding globulin (SHBG) . As hyperinsulinaemia plays a significant role of anovulation in PCOS women, clinical improvements can be anticipated following the reduction of serum insulin concentrations (Pasquali and Filicori, 1998) .
Weight loss in obese women with PCOS leads to a reduction of hyperinsulinaemia (Kiddy et al., 1992) . Insulin-sensitizing agents have been tried in the management of PCOS patients. Metformin is used extensively in the management of type II diabetes and can reduce peripheral insulin concentrations whilst improving glucose tolerance and metabolism. A number of studies (Table I) have shown significant improvements in insulin sensitivity and hyperinsulinaemia in obese PCOS women after metformin administration. These improvements were associated with a reduction in serum androgen concentrations and an increase in SHBG concentrations. However, recent studies have failed to show any benefit in terms of insulin concentrations or hormonal and metabolic profiles (Acbay and Gundogdu, 1996; Ehrmann et al., 1997) .
Clomiphene citrate (CC) is usually used as the first-line drug to induce ovulation in women with PCOS. Successful ovulation is achieved in~70-85% of women and 40-50% will conceive (The ESHRE Capri workshop, 1997) . Gonadotrophin treatment can be offered when these anovulatory women fail to respond to CC. The use of gonadotrophin is more expensive and associated with a much higher risk of multiple pregnancy and developing ovarian hyperstimulation syndrome. At present, there are very few studies evaluating the use of metformin in women with CC-resistant polycystic ovaries (PCO). A very recent report (Vandermolen et al., 2001) revealed that the use of metformin significantly increased the ovulation and pregnancy rates from CC treatment in anovulatory women with CC-resistant PCOS. The aims of this prospective, randomized, double blind, placebo-controlled study were to (i) determine the ovulation rate and (ii) examine the changes in hormonal and metabolic profiles, in women with CC-resistant PCO after taking metformin for 3 months. The hypothesis was that women with CC-resistant PCO would experience a significant increase in the ovulation rate after taking metformin for 3 months.
Materials and methods

Protocol
Chinese women attending the Department of Obstetrics & Gynaecology, University of Hong Kong, for infertility treatment were recruited into the study if they fulfilled the following criteria: (i) age of women Ͻ40 years; (ii) Day 2 serum FSH Ͻ10 IU/l; (iii) PCO diagnosed by transvaginal ultrasonography i.e. Ͼ10 follicles of 2-10 mm in diameter and increased density of ovarian stroma (Adams et al., 1985) ; and (iv) irregular cycles and anovulation as shown by mid-luteal progesterone concentrations Ͻ16 nmol/l (Landgren et al., 1980) while on CC 100 mg daily for 5 days over three cycles. Bilateral patent Fallopian tubes were confirmed in all women by both laparoscopy and dye test. Husbands of subjects all had normal semen variables (WHO, 1992) . Exclusion criteria were smokers, or those suffering from renal impairment or taking sex hormones within the last 3 months. Every patient gave written informed consent prior to participating in the study, which was approved by the Ethics Committee, Faculty of Medicine, The University of Hong Kong.
Baseline screening tests were performed on the second day of a spontaneous period or progestogen-induced withdrawal bleeding. Transvaginal scanning was performed using a 5 MHz vaginal probe (Aloka, Model SSD-620, Aloka Co. Ltd., Tokyo, Japan) to measure the length, height and width of each ovary in the sagittal and coronal planes. The ovarian volume was obtained using a formula for the volume of an ellipsoid (π/6ϫlengthϫheightϫwidth) and the volume of both ovaries gave the total ovarian volume. Blood was then taken for: (i) hormonal profile-serum FSH, LH, testosterone, androstenedione, dehydroepiandrosterone-sulphate (DHEAS), SHBG, fasting insulin and fasting leptin; and (ii) metabolic profile-fasting glucose and 2 hour glucose after 75 g oral glucose load, fasting cholesterol, triglycerides (TG), high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol.
Assignment
Women were randomized according to a computer-generated randomization list in sealed envelopes to receive either placebo or metformin (Lipha Santè, Lyon, France) 500 mg three times a day for 3 months. Blood was taken weekly for serum progesterone and ovulation was considered to be present if serum progesterone concentrations were Ͼ16 nmol/l. Body weight, menstrual pattern and side-effects such as nausea, vomiting and diarrhoea were recorded at each monthly out-patient visit. Pregnancy tests were carried out in those having ovulatory responses. Once the patient was found to be pregnant, the drug was discontinued and pelvic ultrasound was arranged to confirm an intrauterine pregnancy.
The above hormonal and metabolic tests were repeated in women who were not pregnant after three months of therapy (placebo and metformin). CC (Clomid, Merrell, Staines, Middlesex, UK) 100 mg for 5 days was then started in only those women who had no evidence 1627 of ovulation after three months of therapy. Ovulation was determined again by measuring serum progesterone concentrations. If there was still no ovulation after CC treatment for one cycle, the woman was advised to have gonadotrophin treatment.
Concentrations of glucose and lipids were measured in the hospital laboratory. Hormonal parameters were determined in duplicate on a single batch of frozen (-20°C) stored samples. Serum FSH, LH and progesterone concentrations were determined by immunoassay using direct chemiluminometric technology (Chiron Diagnostics Corporation, East Walpole, MA, USA). Serum testosterone, androstenedione, DHEAS, SHBG and insulin were measured by radioimmunoassay (Diagnostic Products Corporation, Los Angeles, CA, USA) as was serum leptin (Linco Research, St Louis, MO, USA).
Masking
Both the women and the doctor were blinded to the content of tablets, which had identical appearance and were packaged by the hospital pharmacist. The codes for the drugs were unblinded only after the completion of the study and statistical analysis.
Statistical analysis
It has been demonstrated that 31 of the 35 women (89%) treated with metformin ovulated spontaneously or in response to CC, compared with 3 of the 26 women (12%) treated with placebo (Nestler et al., 1998) . Assuming similar ovulatory responses in women with CCresistant PCO, the sample size required would be 8 in each group to give a test of significance of 0.05 and a power of 0.8 (Sigmastat, Jandel Scientific, San Rafael, CA, USA). Ten women were recruited in each group. The outcome measures were ovulation rate, as well as hormonal and metabolic profiles. Ovulation rates were calculated as [(luteal weeks/observation weeks)ϫ100]. The maximum ovulation rate possible was 50% in a woman with regular menstrual pattern having a cycle of two follicular and two luteal weeks. Continuous variables were not normally distributed and are given as median (range), unless indicated. Statistical comparison was carried out on an intention to treat basis by Mann-Whitney U-test, χ 2 -test and Wilcoxon ranked sum test, as appropriate. P value (two-tailed) of Ͻ 0.05 was taken as significant.
Results
Participant flow
Twenty women were recruited between January 1999 to December 1999: 10 in the placebo group and 10 in the metformin group. Two women (one from each group) declined to participate shortly after the screening tests because of personal reasons.
Analysis
Both groups were comparable with respect to age of women, duration of infertility, proportion of primary/secondary infertility, total ovarian volume, baseline body mass index (BMI), baseline hormonal and metabolic profiles (Table II and Table  III) . Seven women (70.0%) in the placebo group had evidence of ovulation during the study period: three with placebo only and another four with placebo and CC. Four women (40.0%) in the metformin group had evidence of ovulation: three with metformin only and another one with metformin and CC. The median ovulation rate in the placebo group was 0% (0-50.0%) after placebo only and 6.9% (0-50.0%) after placebo and CC whereas the corresponding rates in the metformin group were 0% (0-22.2%) and 0% (0-22.2%) respectively. No significant differences were found in the number of women having evidence of ovulation and the ovulation rates between two groups after placebo/metformin alone and with CC. Two women in the placebo group and one woman in the metformin group became pregnant within 3 months of therapy. Therefore, seven women in the placebo group and eight women in the metformin group were subject to repeated tests of hormonal and metabolic profiles. In the placebo group, the only significant finding was an increase in serum testosterone concentrations while in the metformin group, there were significant decrease in BMI, serum testosterone concentration, and fasting leptin concentration after three months (Table IV) .
Only one woman in the placebo group experienced nausea during the therapy, whilst in the metformin group three women had nausea and another two noted diarrhoea. No women stopped treatment because of side-effects. All three pregnancies resulted in normal deliveries.
Discussion
Most of the studies addressing the use of metformin in patients with PCO have been observational and focused on the menstrual pattern and hormonal profile. Ovulation rate has rarely been documented, especially using objective criteria such as serum progesterone concentration. There have been only four randomized studies published in the literature but their results are conflicting. Crave et al. (1995) found no change in the hormonal and metabolic profiles of 24 obese hirsute women on dieting, who were randomized to receive placebo or metformin. Only 15 of these women had ultrasound features of PCO (Crave et al., 1995) . On the other hand, Nestler et al. (1998) demonstrated that in obese PCOS women the use of metformin significantly improved the ovulation rate and increased the SHBG concentration when compared with the control. Other hormonal and metabolic profiles remained unchanged (Nestler et al., 1998) . Similarly, Moghetti et al. (2000) reported a significant increase in the ovulation rate, decrease in serum testosterone concentration and fasting insulin concentration, and an increase in HDL after taking metformin (Moghetti et al., 2000) .
In a randomized placebo-controlled study, Vandermolen et al. (2001) first reported significant improvements in ovulation and pregnancy rates from CC treatment after taking metformin in women with CC-resistant PCO. The women that enrolled in the study were anovulatory in response to a 5 day course of CC, 150 mg daily and were given increasing doses of CC from 50 to 150 mg daily if they were still anovulatory 6.2 (1.7-9.6) 5.6 (3.4-8.9) 6.7 (3.7-7.8) 5.4 (3.0-8.7) LH (IU/l) 11.3 (5.9-14.4) 13.0 (9.0-22.5) 10.0 (5.3-23.2) 9.7 (3.1-24.6) Testosterone (nmol/l) 1.3 b (0.5-2.2) 1.5 b (1.0-2.6) 1.8 b (1.0-3.7) 1.2 b (0.6-2.3) Androstenedione (nmol/l) 8.7 (6.4-13.2) 9.8 (7.3-12.6) 9.2 (6.6-12.6) 8.5 (4.6-11.3) DHEAS (µmol/l) 4.9 (2.4-9.1) 3.8 (1.0-6.8) 5.9 (0.8-9.7) 7.0 (3.8-9.6) SHBG (nmol/l) 36.6 (15.5-52.7) 32.9 (14.3-60.2) 28.7 (9.0-47.1) 26.6 (10.4-45.9) Fasting insulin (mIU/l) 12.1 (2.8-17.0) 7.3 (5.2-21.9) 10.8 (4.7-19.7) 8.2 (3.9-9.0) Fasting leptin (µg/l) 10.4 (2.3-16.2) 10.5 (3.1-17.9) 10.2 a (7.8-24.3) 7.9 a (3.8-13.5) Fasting sugar (mmol/l) 5.3 (3.2-6.1) 4.9 (4.4-5.7) 5.2 (4.6-7.1) 5.1 (4.6-5.6) 2hr sugar after OGTT (mmol/l) 6.4 (5.1-15.1) 5.8 (3.5-7.7) 7.4 (3.5-15.1) 7.7 (5.6-11.2) Fasting cholesterol (mmol/l) 4.7 (3.7-5.4) 4.9 (3.7-8.4) 5.1 (3.8-5.7) 4.4 (3.5-6.1) Fasting triglycerides (mmol/l) 1.1 (0.5-1.6) 1.1 (0.4-2.2) 1.0 (0.4-2.6) 1.0 (0.4-1.5) Fasting HDL (mmol/l) 1.2 (0.8-1.6) 1.2 (0.9-1.9) 1.1 (0.7-2.1) 1.6 (0.8-1.9) Fasting LDL (mmol/l) 3.0 (2.0-3.5) 3.4 (1.9-6.2) 3.0 (2.2-3.8) 2.5 (1.8-4.3) a P Ͻ 0.01 by Wilcoxon ranked sum test. b P Ͻ 0.05 by Wilcoxon ranked sum test. DHEAS ϭ dehydroepiandrosterone-sulphate; SHBG ϭ sex hormone-binding globulin; OGTT ϭ oral glucose tolerance test; HDL ϭ high-density lipoprotein; LDL ϭ low-density lipoprotein.
after taking metformin. In the metformin and placebo groups, nine of 12 women (75%) and four of 15 women (27%) ovulated and six of 11 women (55%) and 1 of 14 women (7%) conceived respectively (Vandermolen et al., 2001) . In contrast, here we report no improvement in the number of women having evidence of ovulation and in the ovulation rate in women with CC-resistant PCO after metformin alone or with CC, when compared to the placebo. Women in the metformin group showed a significant decrease in BMI, serum testosterone concentration and fasting leptin concentration after 3 months, whereas those in the placebo group experienced a significant increase in serum testosterone concentration. Our results implied that metformin may not be useful for ovulation induction in all women with CCresistant PCO, although it has been successfully used as the first-line therapy to induce ovulation in PCOS patients (Nestler et al., 1998; Moghetti et al., 2000) .
In this study, only 100 mg of CC was tried because previous reports have demonstrated that patients failing to respond to this dose do not ovulate when given higher doses (Polson et al., 1979) . It remains uncertain whether ovulation rate in the metformin group would have increased if the dose of CC was given in a step-up fashion as was used in the study by Vandermolen et al. mentioned above (Vandermolen et al., 2001 ). The discrepancy of our finding from other studies may be also due to recruitment of women with CC-resistant PCO, diagnosis of PCO by ultrasound criteria only and inclusion of non-obese women in this study. Non-responders to CC may represent a more resistant form of PCO (Mitwally et al., 1999) . Non-responders are more likely to be obese (Lobo et al., 1982) and have greater ovarian volumes and greater numbers of small follicles on ultrasound examination (Fiçicioglu et al., 1996) than responders. Concentrations of serum LH or androgens 1629 have not differed consistently between responders and nonresponders (Polson et al., 1979; Lobo et al., 1982; Fiçicioglu et al., 1996) .
There is substantial heterogeneity of symptoms and signs among women with PCOS and different criteria have been used to confirm the diagnosis. Ultrasound assessment of ovarian morphology is considered to be essential and has become the gold standard for defining PCO (Adams et al., 1985; Homburg, 1996; Balen, 1999) . Characteristic ovarian morphology is not required in the American definition, which states that PCOS is the association of hyperandrogenism with chronic anovulation in women without specific underlying diseases of the adrenal or pituitary glands (Dunaif, 1997) . Hyperandrogenism, characterized clinically by hirsutism or biochemically by elevated serum concentrations of androgens, was included as one of selection criteria in many studies on the use of metformin in PCOS (Table I) .
Metformin treatment seemed to have no effect on ovarian function in women with normal testosterone concentrations whereas patients with elevated pretreatment testosterone concentrations showed the most marked increase in ovulation rate (Pirwany et al., 1999) . Serum androgen concentrations may be normal in 30-50% of women with oligomenorrhea with PCO (Robinson et al., 1992) . The majority of our patients did not have clinical or laboratory features of hyperandrogenism. This may also explain the absence of ovarian response to metformin in this study. Similar to other studies, serum testosterone concentrations were significantly reduced in the metformin group after 3 months. Significant heterogeneity in the hormonal and metabolic responses after metformin was observed (Table I) . Interestingly, there was a significant increase of serum testosterone in the placebo group but the reason for this change is unknown.
Obese PCOS women with average BMI ranging from 27 to 37 kg/m 2 were recruited in many studies (Table I ). The median BMI in this study was only 24 kg/m 2 , ranging from 17.9 to 34.2 kg/m 2 . The ability of metformin to alter insulin sensitivity seems to depend on the body weight and it has been reported (Kahn et al., 1993) that substantial reductions in BMI were required to improve insulin sensitivity in individuals whose BMI exceeded 30 kg/m 2 . Although improvement in insulin sensitivity was also observed in lean women with PCOS after metformin (Nestler and Jakubowicz, 1997) , it remains uncertain whether ovulation rate can be improved in these women also. The significant reduction of fasting leptin concentration in the metformin group may be the result of the decrease in BMI. There was no change in the lipid profile after 3 months of metformin and a longer duration up to 6 months may increase HDL (Moghetti et al., 2000) . This has significant implications in the long-term management of patients with PCOS as they are more prone to hypertension and diabetes mellitus (Dahlgren et al., 1992; Mather et al., 2000) . Troglitazone, another insulin-sensitizing agent, has been shown to induce ovulation in 15 of 18 (83%) women with CC-resistant PCOS (Mitwally et al., 1999) . Different insulinsensitizing agents have different mechanisms of action. The major action of metformin is to reduce gluconeogenesis, resulting in decreased hepatic glucose production whilst troglitazone improves muscle insulin sensitivity and total body insulin action (Dunaif et al., 1996) , after amelioration of defects in insulin action and insulin secretion. Because of the risk of hepatic damage due to an idiosyncratic reaction, troglitazone has been withdrawn from the market.
In summary, metformin treatment for 3 months in women with CC-resistant PCO showed no improvement in the ovulation rate despite significant reduction of BMI, serum testosterone and fasting leptin concentrations. Metformin may not be indicated to induce ovulation in women with PCO after they failed to respond to CC. Ovulation induction may be successful in certain subgroups such as obese women or women with hyperandrogenism. Further studies are required to clarify these issues.
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